LTE Partners, LLC 4
4 · PROGENICS PHARMACEUTICALS INC · Filed Sep 9, 2019
Insider Transaction Report
Form 4
LTE Partners, LLC
10% OwnerOther
Transactions
- Purchase
Common Stock, $0.0013 par value
2019-09-09$4.94/sh+21,480$106,096→ 1,950,000 total - Purchase
Common Stock, $0.0013 par value
2019-09-05$4.62/sh+43,520$201,097→ 1,928,520 total
Footnotes (2)
- [F1]This Form 4 is filed jointly by LTE Partners, LLC ("LTE"), Melkonian Capital Management, LLC ("MCM"), LTE Management, LLC ("LTE Management"), and Ryan Melkonian (collectively, the "Reporting Persons"). The Reporting Persons may be deemed to be members of a Section 13(d) group that collectively beneficially owns more than 10% of the Issuer's outstanding shares of Common Stock. The Reporting Persons disclaim beneficial ownership of the securities of the Issuer owned directly by other members of the Section 13(d) group and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 or for any other purpose. Further, the Reporting Persons expressly disclaim beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.
- [F2]Securities owned directly by LTE. Each of MCM, as the sole investment advisor to LTE, and LTE Management, as the sole manager of LTE, may be deemed tobeneficially own the securities owned directly by LTE. Mr. Melkonian, in his capacities as (i) the sole manager and majority member of LTE Management and (ii) the Chief Investment Officer, Management Member and majority owner of MCM, may also be deemed to beneficially own the securities owned directly by LTE.